Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab in advanced ovarian cancer
NCT05605535Phase 2Active, not recruiting
- Sponsor
- CanariaBio
- Start
- Feb 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) comparing Combination of Oregovomab and chemotherapy with Combination of Placebo and chemotherapy (2 arms). Primary endpoint: Progression-free survival Rate at 12 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05605535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605535.